경구 고형 제제 수탁제조 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 메커니즘별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Oral Solid Dosage Contract Manufacturing Market Growth & Trends:

The global oral solid dosage contract manufacturing market size is estimated to reach USD 54.72 billion by 2030, registering a CAGR of 5.99% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing complexity of new drug molecules, R&D investments by large CMOs & CDMOs and rising demand for novel therapies are key factors driving market growth.

Oral solids are widely accepted dosage forms in the pharmaceutical sector since they are cost-effective, simple to manufacture, and patient-friendly. Furthermore, advances in drug delivery technology, such as control release and sustained release formation, are enabling oral solids to achieve even higher levels of bioavailability while lowering drug administration frequency. Thereby, it is anticipated to propel market growth potential.

Technological advancements in the development and bulk manufacturing of oral solid dosage forms are among the primary factors supporting the fast-track commercialization of these products. Currently, a diverse array of dosage forms is accessible in the market. However, the nutraceutical and pharmaceutical industries consistently put effort into developing OSD forms. This preference is due to their ease of handling, convenient consumption, and positive patient adherence. Anticipated advancements in technology and materials of OSD forms are projected to boost the demand for these formulations.

Furthermore, R&D investments by CMOs and CDMOs contribute to enhanced innovation in manufacturing processes, formulation development, & analytical technologies. This can lead to the adoption of more efficient and advanced manufacturing techniques in the production of oral solid dosage forms. Also, investments in R&D result in the expansion of manufacturing capabilities and improved scalability. This allows CMOs and CDMOs to offer larger volumes of oral solid dosage production to meet the increasing demand from pharmaceutical companies.

Moreover, the industry witnessed many strategic movements in 2023, such as collaborations, partnerships, M&As, service expansion, etc.

• In July 2023, Aenova Group and Galvita entered a strategic partnership to improve the formulation, production, and development of oral dosage forms.
• In April 2023, Aenova invested approximately USD 21.96 million (20 million euros) to expand its high-volume solids site in Tittmoning, resulting in increased capacity.
• In January 2023, Catalent and Ethicann collaborated to develop Ethicann's clinical drug pipeline using Catalent's technology known as Orally Disintegrating Tablet (ODT) technology.

Oral Solid Dosage Contract Manufacturing Market Report Highlights:

• The tablets segment dominated the market with a revenue share of 32.74% in 2024. Tablets are the most common and preferred OSD form due to their cost-effectiveness, high compactness, easy manufacturing, and convenience of self-administration. Increased demand for bilayer tablets and investments by firms to expand formulation and controlled-release tablet manufacturing are predicted to drive market growth.
• The controlled release segment accounted for the largest share in 2024. This growth is attributed to advancements in oral controlled release delivery systems, including dome tablets, dual drug tablets, intestinal patches, polymer nanosystems, and bioinspired delivery methods, such as exosomes for precise drug delivery. Thus, high demand for control release dosage forms is anticipated to boost segmental revenue growth in the near future.
• Based on end-use, the large size companies segment accounted for the largest share in 2024. The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and high adaptability. More pharma developers design drugs from the start, intending to outsource them to large CMOs, thereby accelerating market growth. Furthermore, CMOs specializing in oral solid dosage can provide several benefits to large pharmaceutical companies, leading to their increased adoption.
• Asia Pacific led the global market in 2024 and is projected to witness the fastest CAGR over the forecast period. China and India are the powerhouses of oral solid dosage contract manufacturing organizations with significantly lower prices. Further, expanding manufacturing capabilities among Asian countries such as Singapore, India, and South Korea have been considered major players in the pharmaceutical industry due to their expanding manufacturing capabilities.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Information Analysis
  • 1.4.2. Market Formulation & Data Visualization
  • 1.4.3. Data Validation & Publishing
• 1.5. Model Details
  • 1.5.1. Commodity Flow Analysis (Model 1)
  • 1.5.2. Top Down Market Estimation (Model 2)
  • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
  • 1.5.4. Multivariate Analysis (Model 4)
• 1.6. List of Secondary Sources
• 1.7. List of Abbreviations
• 1.8. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. Technological Advancements in Oral Solid Dosage (OSD) Forms
    • 3.3.1.2. Expansion of Manufacturing Capacity by CMOs & CDMOs for OSD
    • 3.3.1.3. Increasing Demand for Novel Therapies
    • 3.3.1.4. Increasing Demand for One-Stop-Shop CMOs
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. Strict Approval Criteria by Regulatory Authorities
    • 3.3.2.2. Lack of Experienced Technical Staff, Physical Capability, and Equipment Capacity
    • 3.3.2.3. Increasing Need for Biosimilars and Their Prominence in Addressing Cancer & Other Medical Conditions
• 3.4. Technology Landscape
  • 3.4.1. Manufacturing Technology
  • 3.4.2. Encapsulation Technology
  • 3.4.3. Coating Technology
  • 3.4.4. Packaging Technology
  • 3.4.5. Analytical Technology
• 3.5. Pricing Model Analysis
• 3.6. Industry Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Oral Solid Dosage Contract Manufacturing Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Oral Solid Dosage Contract Manufacturing Market; Product Movement Analysis
• 4.3. Oral Solid Dosage Contract Manufacturing Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Tablets
  • 4.4.1. Tablets market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Capsules
  • 4.5.1. Capsules market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.6. Powders
  • 4.6.1. Powders market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.7. Granules
  • 4.7.1. Granules market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Oral Solid Dosage Contract Manufacturing Market: Mechanism Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Oral Solid Dosage Contract Manufacturing Market; Mechanism Movement Analysis
• 5.3. Oral Solid Dosage Contract Manufacturing Size & Trend Analysis, by Mechanism, 2018 to 2030 (USD Million)
• 5.4. Immediate Release
  • 5.4.1. Immediate release market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Delayed Release
    • 5.4.2.1. Delayed release market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Controlled Release
    • 5.4.3.1. Controlled release market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Oral Solid Dosage Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Oral Solid Dosage Contract Manufacturing Market; End Use Movement Analysis
• 6.3. Oral Solid Dosage Contract Manufacturing Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Large Size Companies
  • 6.4.1. Large size companies market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Medium & Small Size Companies
  • 6.5.1. Medium & small size companies market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Oral Solid Dosage Contract Manufacturing Market: Regional Business Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. North America oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. U.S. oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Canada oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Mexico oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Germany oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. UK
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. UK oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. France oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Italy oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Spain oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Denmark oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Sweden oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Norway oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Japan oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. China oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. India oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. South Korea oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Australia oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Thailand oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Brazil oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Argentina oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. South Africa oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Saudi Arabia oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. UAE oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Kuwait oral solid dosage contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Catalent, Inc.
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Lonza
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Aenova Group
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Boehringer Ingelheim International GmbH
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Jubilant Pharmova Limited
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Patheon Pharma Services
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Recipharm AB.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Corden Pharma International
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Siegfried Holding AG
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Piramal Pharma Solutions
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. AbbVie Contract Manufacturing
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Service benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Next Pharma AB
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Service benchmarking
    • 8.3.12.4. Strategic initiatives